Immunotherapy in Renal Cell Carcinoma

Jennifer Cudris, Jaime R. Merchan

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Renal cell carcinoma (RCC) is a chemotherapy-resistant disease, and current molecularly targeted therapies offer limited clinical benefit but no cures. The observation that RCC is immunogenic led to immune-based strategies for the treatment of this disease. Immunotherapy with high-dose IL-2 can induce long-term, complete responses in a small percentage of patients. IFN has been used as an immune intervention as well but with much less success than IL-2. Currently IFN is used only in combination with the anti-VEGF monoclonal antibody bevacizumab. Further investigation of novel immune interventions in RCC is ongoing with promising results. Dendritic cell vaccines have been tested in single-arm clinical trials suggesting improved survival when added to standard anti-angiogenic therapy. Monoclonal antibodies against PD-1 and PD-L1, novel immune targets, have shown promising response in phase I trials. Peptide vaccines have shown efficacy in phase II trials as well. Phase III trials to test these immune interventions are currently ongoing and have the potential to bring new, effective treatment options for patients with advanced RCC.

Original languageEnglish (US)
Title of host publicationAdvances in Tumor Immunology and Immunotherapy
PublisherHumana Press Inc.
Pages125-147
Number of pages23
ISBN (Print)9781461488088
DOIs
StatePublished - Jan 1 2014

Publication series

NameCurrent Cancer Research
Volume12
ISSN (Print)0940-0745

Keywords

  • Clinical trials
  • IL-2
  • Immunotherapy
  • Renal Cell Carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Immunotherapy in Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this